Company

Roche

Pharmaceutical intelligence for Roche with 75 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 37
Catalysts: 38
Assets: 26

Recent signals(37)

ClinicalJune 20, 2026

Venetoclax-Dexamethasone Trial for t(11;14) Relapsed/Refractory Amyloidosis Initiated

A clinical trial is underway to evaluate the safety and efficacy of venetoclax combined with dexamethasone for relapsed or refractory t(11;14) light chain amyloidosis.

RegulatoryJune 19, 2026

FDA Accepts Supplemental Application for ALECENSA (Alectinib Hydrochloride)

The FDA has accepted a supplemental application for ALECENSA, indicating ongoing development and potential label expansion.

ClinicalJune 18, 2026

Risdiplam Study to Assess Real-World Outcomes in Type I and II SMA

A multicenter study will evaluate the real-world clinical outcomes and safety of Risdiplam in SMA patients over 24 months.

ClinicalJune 18, 2026

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

The RAPTOR trial is assessing the efficacy of adding radiation therapy to atezolizumab maintenance in extensive stage small cell lung cancer.

RegulatoryJune 18, 2026

FDA Accepts Supplement Application for ENSPRYNG (Satralizumab)

The FDA has accepted the supplemental application for ENSPRYNG (satralizumab) submitted by Genentech.

ClinicalJune 18, 2026

Genentech initiates study on progression of intermediate age-related macular degeneration

Genentech is conducting a multicenter observational study to assess disease progression in intermediate age-related macular degeneration over approximately 3 years.

ClinicalJune 18, 2026

Phase III Trial of Atezolizumab with Chemotherapy for Metastatic Colorectal Cancer Initiated

The COMMIT study is evaluating the efficacy of atezolizumab in combination with chemotherapy and bevacizumab for metastatic colorectal cancer with DNA mismatch repair deficiency.

ClinicalJune 18, 2026

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

ClinicalJune 17, 2026

Study on Early Rehabilitation Protocol for Breast Cancer Surgery Shows Promising Safety and Feasibility

A new early rehabilitation protocol, EMOVE-BCS-LaFe, is being evaluated for safety and feasibility in breast cancer surgery patients.

ClinicalJune 17, 2026

STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism

STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.

ClinicalJune 17, 2026

Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines

A multi-center, retrospective study will analyze real-world data from 3,500 patients with breast phyllodes tumors in China.

ClinicalJune 17, 2026

Phase III Trial Compares 6 vs. 12 Months of HER2-Targeted Therapy in Breast Cancer

A phase III trial is investigating whether 6 months of HER2-targeted therapy is more effective than 12 months for HER2-positive breast cancer patients who achieved a pathologic complete response after neoadjuvant chemotherapy.

ClinicalJune 17, 2026

Phase III Trial of Herceptin Hylecta or Phesgo with Chemotherapy for HER2 Positive Endometrial Cancer

A phase III trial is testing the efficacy of adding Herceptin Hylecta or Phesgo to standard chemotherapy in HER2 positive endometrial cancer.

RegulatoryJune 17, 2026

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment

The FDA has accepted Roche's sBLA for Gazyva/Gazyvaro, based on phase III ALLEGORY data showing significant efficacy in SLE.

ClinicalJune 17, 2026

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study

The Phase III METEOROID study demonstrated that ENSPRYNG (satralizumab) reduced the risk of relapses by 68% in MOGAD patients.

StrategyJune 17, 2026

Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics

Roche's Q1 2026 sales grew 6% at constant exchange rates, driven by strong demand for innovative medicines, particularly in multiple sclerosis and oncology.

ClinicalJune 17, 2026

Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer

A phase II trial is underway to compare the efficacy and safety of FOLFOX8 versus mFOLFOX6 with bevacizumab or cetuximab in patients with unresectable metastatic colorectal cancer.

CompetitiveJune 17, 2026

Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development

Antibody-drug conjugates (ADCs) have shown significant clinical benefits in advanced phase trials for various cancers, with over a dozen receiving FDA approval.

StrategyJune 17, 2026

Roche Presents New Data on Vabysmo and Susvimo at ARVO 2026

New real-world data confirm Vabysmo's effectiveness in drying the retina for nAMD and DME, while Susvimo shows potential for sustained disease control.

ClinicalJune 16, 2026

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche will present new Phase II data for enicepatide and petrelintide in obesity at the ADA Scientific Sessions.

CompetitiveJune 16, 2026

Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics

Roche has entered into a definitive agreement to acquire PathAI for $750 million, enhancing its digital pathology capabilities.

StrategyJune 16, 2026

Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics

Roche has entered into a definitive merger agreement to acquire PathAI for $750 million, enhancing its digital pathology capabilities.

CompetitiveJune 16, 2026

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche will present new data from the Phase II studies of enicepatide and petrelintide in obesity at the ADA Scientific Sessions.

RegulatoryJune 16, 2026

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection

Roche has received CE Mark approval for Elecsys® pTau217, the first blood test designed to detect Alzheimer's disease pathology.

RegulatoryJune 16, 2026

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

Roche has received CE Mark approval for Elecsys® pTau217, the first blood test for Alzheimer's disease pathology, enabling faster diagnosis.

CompetitiveJune 16, 2026

Roche Launches Liver Disease Panel to Enhance Chronic Liver Disease Management

Roche has launched the Liver Disease Panel, a suite of certified algorithms aimed at improving the management of chronic liver disease (CLD). This panel includes the LiverPRO algorithm, which facilitates early detection of liver fibrosis using routine blood markers.

CompetitiveJune 16, 2026

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

CompetitiveJune 16, 2026

Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

StrategyJune 16, 2026

Roche and Nurix Collaborate on BTK Degrader Bexobrutideg for B-cell Malignancies

Roche has entered a collaboration with Nurix Therapeutics to co-develop bexobrutideg, BTK degrader targeting B-cell malignancies, immunology, and neurology.

StrategyJune 16, 2026

Roche and Nurix Collaborate on BTK Degrader Bexobrutideg for B-cell Malignancies

Roche has entered a collaboration with Nurix Therapeutics to co-develop bexobrutideg, a novel BTK degrader targeting B-cell malignancies, immunology, and neurology.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, indicating giredestrant's potential as a new standard of care in early and advanced ER-positive breast cancer.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, highlighting giredestrant's potential as a new standard of care for ER-positive breast cancer.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, an oral SERD, under priority review based on phase III data showing a 30% reduction in invasive disease recurrence or death compared to standard therapy.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, showing a 30% reduction in invasive disease recurrence compared to standard therapy.

RegulatoryJune 13, 2026

Roche's VENTANA PTEN Assay Receives FDA Approval for Prostate Cancer Companion Diagnostic

Roche's VENTANA PTEN (SP218) RxDx Assay is the first FDA-approved companion diagnostic for assessing PTEN protein loss in prostate cancer.

RegulatoryJune 11, 2026

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer

The FDA has accepted Roche's sBLA for Tecentriq plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

RegulatoryJune 11, 2026

FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer

The FDA has accepted Roche's sBLA for Tecentriq in combination with chemotherapy for stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

Upcoming catalysts(1)

Priority Review

Roche — Tecentriq

Priority review accelerates competitive pressure in adjuvant IO colon cancer.

June 28, 2026 · NDA/BLA

Regulatory activity(10)

RegulatoryJune 19, 2026

FDA Accepts Supplemental Application for ALECENSA (Alectinib Hydrochloride)

The FDA has accepted a supplemental application for ALECENSA, indicating ongoing development and potential label expansion.

RegulatoryJune 18, 2026

FDA Accepts Supplement Application for ENSPRYNG (Satralizumab)

The FDA has accepted the supplemental application for ENSPRYNG (satralizumab) submitted by Genentech.

RegulatoryJune 17, 2026

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment

The FDA has accepted Roche's sBLA for Gazyva/Gazyvaro, based on phase III ALLEGORY data showing significant efficacy in SLE.

RegulatoryJune 16, 2026

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection

Roche has received CE Mark approval for Elecsys® pTau217, the first blood test designed to detect Alzheimer's disease pathology.

RegulatoryJune 16, 2026

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

Roche has received CE Mark approval for Elecsys® pTau217, the first blood test for Alzheimer's disease pathology, enabling faster diagnosis.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, showing a 30% reduction in invasive disease recurrence compared to standard therapy.

RegulatoryJune 13, 2026

Roche's VENTANA PTEN Assay Receives FDA Approval for Prostate Cancer Companion Diagnostic

Roche's VENTANA PTEN (SP218) RxDx Assay is the first FDA-approved companion diagnostic for assessing PTEN protein loss in prostate cancer.

RegulatoryJune 11, 2026

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer

The FDA has accepted Roche's sBLA for Tecentriq plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

RegulatoryJune 11, 2026

FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer

The FDA has accepted Roche's sBLA for Tecentriq in combination with chemotherapy for stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

Clinical activity(16)

ClinicalJune 20, 2026

Venetoclax-Dexamethasone Trial for t(11;14) Relapsed/Refractory Amyloidosis Initiated

A clinical trial is underway to evaluate the safety and efficacy of venetoclax combined with dexamethasone for relapsed or refractory t(11;14) light chain amyloidosis.

ClinicalJune 18, 2026

Risdiplam Study to Assess Real-World Outcomes in Type I and II SMA

A multicenter study will evaluate the real-world clinical outcomes and safety of Risdiplam in SMA patients over 24 months.

ClinicalJune 18, 2026

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

The RAPTOR trial is assessing the efficacy of adding radiation therapy to atezolizumab maintenance in extensive stage small cell lung cancer.

ClinicalJune 18, 2026

Genentech initiates study on progression of intermediate age-related macular degeneration

Genentech is conducting a multicenter observational study to assess disease progression in intermediate age-related macular degeneration over approximately 3 years.

ClinicalJune 18, 2026

Phase III Trial of Atezolizumab with Chemotherapy for Metastatic Colorectal Cancer Initiated

The COMMIT study is evaluating the efficacy of atezolizumab in combination with chemotherapy and bevacizumab for metastatic colorectal cancer with DNA mismatch repair deficiency.

ClinicalJune 18, 2026

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

ClinicalJune 17, 2026

Study on Early Rehabilitation Protocol for Breast Cancer Surgery Shows Promising Safety and Feasibility

A new early rehabilitation protocol, EMOVE-BCS-LaFe, is being evaluated for safety and feasibility in breast cancer surgery patients.

ClinicalJune 17, 2026

STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism

STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.

ClinicalJune 17, 2026

Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines

A multi-center, retrospective study will analyze real-world data from 3,500 patients with breast phyllodes tumors in China.

ClinicalJune 17, 2026

Phase III Trial Compares 6 vs. 12 Months of HER2-Targeted Therapy in Breast Cancer

ClinicalJune 17, 2026

Phase III Trial of Herceptin Hylecta or Phesgo with Chemotherapy for HER2 Positive Endometrial Cancer

A phase III trial is testing the efficacy of adding Herceptin Hylecta or Phesgo to standard chemotherapy in HER2 positive endometrial cancer.

ClinicalJune 17, 2026

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study

The Phase III METEOROID study demonstrated that ENSPRYNG (satralizumab) reduced the risk of relapses by 68% in MOGAD patients.

ClinicalJune 17, 2026

Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer

A phase II trial is underway to compare the efficacy and safety of FOLFOX8 versus mFOLFOX6 with bevacizumab or cetuximab in patients with unresectable metastatic colorectal cancer.

ClinicalJune 16, 2026

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche will present new Phase II data for enicepatide and petrelintide in obesity at the ADA Scientific Sessions.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, indicating giredestrant's potential as a new standard of care in early and advanced ER-positive breast cancer.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, highlighting giredestrant's potential as a new standard of care for ER-positive breast cancer.